
Hims & Hers Health (HIMS) shares are extending gains on April 16 after HHS Secretary Robert F. Kennedy Jr. said the Food and Drug Administration (FDA) is considering removing restrictions on more than half a dozen peptides.
Following this surge, HIMS is trading a little under its 100-day moving average (MA), with a clear break above $27 expected to accelerate bullish momentum in the near term.